121,400 Shares in Climb Bio, Inc. $CLYM Purchased by ArchPoint Investors

ArchPoint Investors acquired a new position in Climb Bio, Inc. (NASDAQ:CLYM) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 121,400 shares of the company’s stock, valued at approximately $486,000.

Other large investors also recently bought and sold shares of the company. Peapod Lane Capital LLC grew its stake in shares of Climb Bio by 0.7% during the 4th quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock valued at $2,264,000 after purchasing an additional 4,126 shares during the period. ADAR1 Capital Management LLC grew its stake in shares of Climb Bio by 11.9% during the 3rd quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company’s stock valued at $268,000 after purchasing an additional 14,210 shares during the period. AQR Capital Management LLC bought a new stake in shares of Climb Bio during the 1st quarter valued at about $27,000. UBS Group AG grew its stake in shares of Climb Bio by 6.0% during the 3rd quarter. UBS Group AG now owns 405,404 shares of the company’s stock valued at $815,000 after purchasing an additional 22,922 shares during the period. Finally, State Street Corp grew its stake in shares of Climb Bio by 25.0% during the 4th quarter. State Street Corp now owns 128,900 shares of the company’s stock valued at $516,000 after purchasing an additional 25,800 shares during the period. 69.76% of the stock is currently owned by institutional investors.

Climb Bio Stock Up 4.9%

CLYM stock opened at $11.44 on Friday. Climb Bio, Inc. has a twelve month low of $1.16 and a twelve month high of $12.48. The stock has a market cap of $655.05 million, a P/E ratio of -14.67 and a beta of 0.09. The business’s 50-day moving average price is $9.96 and its 200-day moving average price is $6.70.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. On average, equities research analysts expect that Climb Bio, Inc. will post -0.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CLYM shares. Guggenheim started coverage on Climb Bio in a research note on Monday, June 8th. They set a “buy” rating and a $35.00 price target for the company. Mizuho started coverage on Climb Bio in a research note on Wednesday, April 15th. They set an “outperform” rating and a $18.00 price target for the company. Wedbush restated an “outperform” rating and set a $17.00 price target on shares of Climb Bio in a research note on Friday. B. Riley Financial started coverage on Climb Bio in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target for the company. Finally, Raymond James Financial started coverage on Climb Bio in a research note on Tuesday, March 10th. They set a “strong-buy” rating and a $25.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $21.73.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.